Lanreotide Evidence Guide
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.
Our Take
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.
- Evidence context
- Acromegaly, gastroenteropancreatic NETs, somatostatin analog pharmacology, GH/IGF-1 suppression
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 60-120mg deep subcutaneous every 28 days (autogel/depot)
Benefits and Evidence
- Acromegaly Biochemical Control: Level A, includes human evidence - Normalizes GH <=2.5 ng/mL and IGF-1 in approximately 50-65% of treatment-naive acromegaly patients. Extended dosing intervals (every 6-8 weeks) possible in well-controlled patients.
- GEP-NET Tumor Stabilization: Level A, includes human evidence - CLARINET trial showed significant prolongation of progression-free survival vs placebo in nonfunctioning GEP-NETs (median PFS not reached vs 18 months). Antiproliferative benefit independent of antisecretory effects.
- Gastrointestinal Side Effects: Level A, includes human evidence - Diarrhea, abdominal pain, and cholelithiasis are common side effects. Gallstones occur in 15-20% of patients on long-term therapy.
Side Effects and Warnings
- Diarrhea
- Abdominal pain
- Cholelithiasis
- Injection site reactions (nodule, pain)
- Nausea
- Flatulence
- Hyperglycemia
- Gallstones - baseline and periodic gallbladder ultrasound
Research Dosage References
- <strong>Deep subcutaneous injection</strong> - 60-120 mg - Every 28 days - Autogel formulation for acromegaly and GEP-NETs. Start at 90 mg. Adjust dose (60-120 mg) and interval based on response. Self-administration possible with training.
Mechanism of Action
Lanreotide provides sustained somatostatin receptor activation: 1. SSTR2-preferential binding: Primary affinity for somatostatin receptor subtype 2, with moderate affinity for SSTR5 and lower affinity for SSTR1, 3, and 4. 2. Supersaturated gel depot: Upon deep subcutaneous injection, lanreotide forms a drug depot at the injection site that slowly releases peptide over 4 weeks, maintaining therapeutic levels. 3. Antiproliferative effects: Directly inhibits tumor cell proliferation in GEP-NETs through SSTR2-mediated cell cycle arrest, and indirectly by reducing circulating growth factors. 4. Hormonal suppression: Inhibits GH secretion (acromegaly), serotonin and other bioactive peptides (carcinoid), and insulin/glucagon (insulinomas/glucagonomas).
Legal Status
FDA-approved for acromegaly and unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs. Available by prescription. Marketed as Somatuline Depot by Ipsen. Extended indication for carcinoid syndrome.
Primary Sources
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET). N Engl J Med, 2014.
- Lanreotide Autogel for acromegaly: integrated 5-year efficacy and safety data. J Clin Endocrinol Metab, 2014.
- Comparison of lanreotide and octreotide in the treatment of acromegaly. Pituitary, 2008.
Quick Answers
Where is the strongest evidence for Lanreotide?
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data. Evidence context: Acromegaly, gastroenteropancreatic NETs, somatostatin analog pharmacology, GH/IGF-1 suppression.
What are the main side effects of Lanreotide?
Lanreotide side effects and warning signals include Diarrhea, Abdominal pain, Cholelithiasis, Injection site reactions (nodule, pain), and Nausea.
What evidence level is Lanreotide?
Lanreotide is rated Level A; the listed research status is FDA Approved.